CytomX Therapeutics (CTMX) Capital Expenditures (2014 - 2025)

CytomX Therapeutics (CTMX) has 12 years of Capital Expenditures data on file, last reported at $201000.0 in Q4 2025.

• Quarterly Capital Expenditures rose 151.25% year-over-year to $201000.0 in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $101000.0 (down 67.83% YoY) and the FY2025 annual result came in at $220000.0, down 29.03% from the prior year.
• Capital Expenditures grew to $201000.0 in Q4 2025, from -$127000.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $982000.0 in Q1 2021 to a low of -$499000.0 in Q4 2023.
• A 5-year average of $197700.0 and a median of $117000.0 in 2024 frame the typical range for Capital Expenditures.
• Annual changes were most pronounced in 2022 — Capital Expenditures surged 261.4% — and 2025, when it tumbled 768.42%.
• Tracing CTMX's Capital Expenditures over 5 years: stood at $245000.0 in 2021, then retreated by 25.71% to $182000.0 in 2022, then plunged by 374.18% to -$499000.0 in 2023, then jumped by 116.03% to $80000.0 in 2024, then surged by 151.25% to $201000.0 in 2025.
• The last three Capital Expenditures figures came in at $201000.0 (Q4 2025), -$127000.0 (Q3 2025), and $27000.0 (Q2 2025), per Business Quant data.